Long-term cardiac follow-up in survivors of a malignant bone tumour
Background: Longitudinal studies of cardiac function in long-term childhood cancer survivors are scarce and frequently concern a median follow-up shorter than 13 years. Patients and methods: Cardiac assessment was performed in 22 doxorubicin-treated long-term survivors of a malignant bone tumour at...
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2006-10, Vol.17 (10), p.1586-1591 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1591 |
|---|---|
| container_issue | 10 |
| container_start_page | 1586 |
| container_title | Annals of oncology |
| container_volume | 17 |
| creator | Brouwer, CAJ Gietema, JA van den Berg, MP Bink-Boelkens, MTE Elzenga, NJ Haaksma, J Kamps, WA Vonk, JM de Vries, EGE Postma, A |
| description | Background: Longitudinal studies of cardiac function in long-term childhood cancer survivors are scarce and frequently concern a median follow-up shorter than 13 years. Patients and methods: Cardiac assessment was performed in 22 doxorubicin-treated long-term survivors of a malignant bone tumour at median 22 years (range 15–27.5) post-treatment. Age at follow-up was 39 years (range 27–59) and cumulative dose of doxorubicin was 360 mg/m2 (range 225–550). Cardiac function was assessed by echocardiography and (24-h) ECG. The results were compared with those of earlier assessments at 9 years (1992) and 14 years (1997) post-treatment. Results: Systolic dysfunction was found in 27% (9% in 1997; P = 0.02) and diastolic dysfunction in 45% (18% in 1997; P = 0.02). Heart rate variability showed further deterioration compared with earlier results. Conclusions: Twenty-two years after doxorubicin-treatment, bone tumour survivors showed progressive cardiac dysfunction. |
| doi_str_mv | 10.1093/annonc/mdl156 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_196623094</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1141009781</sourcerecordid><originalsourceid>FETCH-LOGICAL-c425t-2f2fb8ac916d4dd954046562982d5f0165d4d96210730cbf7078f14ace5f31d53</originalsourceid><addsrcrecordid>eNpFkF1LwzAUhoMobk4vvZUgeFmX7zaXMtQJG4IoyG5Cmjajs01m0k7991Y63M05cM7D-8IDwCVGtxhJOtXOeWemTVFjLo7AuJ8yyRDDx2CMJKFJyikbgbMYNwghIYk8BSMsMp6mhI7BbOHdOmnL0ECjQ1FpA62va_-VdFtYORi7sKt2PkToLdSw0XW1dtq1MPeuhG3X-C6cgxOr61he7PcEvD3cv87myeL58Wl2t0gMI7xNiCU2z7SRWBSsKCRniAkuiMxIwS3CgvdnKQhGKUUmtylKM4uZNiW3FBecTsD1kLsN_rMrY6s2fbvrKxWWQhCKJOuhZIBM8DGG0qptqBodfhRG6s-YGoypwVjPX-1Du7wpiwO9V9QDN3tAR6NrG7QzVTxwGWGcE3EormJbfv__dfhQIqUpV_P3laIcLfnqZanm9Bc1CoPP</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>196623094</pqid></control><display><type>article</type><title>Long-term cardiac follow-up in survivors of a malignant bone tumour</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Brouwer, CAJ ; Gietema, JA ; van den Berg, MP ; Bink-Boelkens, MTE ; Elzenga, NJ ; Haaksma, J ; Kamps, WA ; Vonk, JM ; de Vries, EGE ; Postma, A</creator><creatorcontrib>Brouwer, CAJ ; Gietema, JA ; van den Berg, MP ; Bink-Boelkens, MTE ; Elzenga, NJ ; Haaksma, J ; Kamps, WA ; Vonk, JM ; de Vries, EGE ; Postma, A</creatorcontrib><description>Background: Longitudinal studies of cardiac function in long-term childhood cancer survivors are scarce and frequently concern a median follow-up shorter than 13 years. Patients and methods: Cardiac assessment was performed in 22 doxorubicin-treated long-term survivors of a malignant bone tumour at median 22 years (range 15–27.5) post-treatment. Age at follow-up was 39 years (range 27–59) and cumulative dose of doxorubicin was 360 mg/m2 (range 225–550). Cardiac function was assessed by echocardiography and (24-h) ECG. The results were compared with those of earlier assessments at 9 years (1992) and 14 years (1997) post-treatment. Results: Systolic dysfunction was found in 27% (9% in 1997; P = 0.02) and diastolic dysfunction in 45% (18% in 1997; P = 0.02). Heart rate variability showed further deterioration compared with earlier results. Conclusions: Twenty-two years after doxorubicin-treatment, bone tumour survivors showed progressive cardiac dysfunction.</description><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdl156</identifier><identifier>PMID: 16857723</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Adolescent ; Adult ; anthracyclines ; Antineoplastic agents ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Blood Pressure - physiology ; Bone Neoplasms - complications ; Bone Neoplasms - drug therapy ; Bone Neoplasms - physiopathology ; bone tumour ; cardiac toxicity ; Child ; Doxorubicin - adverse effects ; Doxorubicin - therapeutic use ; Echocardiography ; Electrocardiography ; Female ; Heart Diseases - chemically induced ; Heart Diseases - etiology ; Humans ; late effects ; longitudinal ; Longitudinal Studies ; Male ; Medical sciences ; Middle Aged ; Osteosarcoma - complications ; Osteosarcoma - drug therapy ; Osteosarcoma - physiopathology ; Pharmacology. Drug treatments ; Survivors ; Time</subject><ispartof>Annals of oncology, 2006-10, Vol.17 (10), p.1586-1591</ispartof><rights>2006 INIST-CNRS</rights><rights>Copyright Oxford University Press(England) Oct 2006</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c425t-2f2fb8ac916d4dd954046562982d5f0165d4d96210730cbf7078f14ace5f31d53</citedby><cites>FETCH-LOGICAL-c425t-2f2fb8ac916d4dd954046562982d5f0165d4d96210730cbf7078f14ace5f31d53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18245526$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16857723$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Brouwer, CAJ</creatorcontrib><creatorcontrib>Gietema, JA</creatorcontrib><creatorcontrib>van den Berg, MP</creatorcontrib><creatorcontrib>Bink-Boelkens, MTE</creatorcontrib><creatorcontrib>Elzenga, NJ</creatorcontrib><creatorcontrib>Haaksma, J</creatorcontrib><creatorcontrib>Kamps, WA</creatorcontrib><creatorcontrib>Vonk, JM</creatorcontrib><creatorcontrib>de Vries, EGE</creatorcontrib><creatorcontrib>Postma, A</creatorcontrib><title>Long-term cardiac follow-up in survivors of a malignant bone tumour</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><description>Background: Longitudinal studies of cardiac function in long-term childhood cancer survivors are scarce and frequently concern a median follow-up shorter than 13 years. Patients and methods: Cardiac assessment was performed in 22 doxorubicin-treated long-term survivors of a malignant bone tumour at median 22 years (range 15–27.5) post-treatment. Age at follow-up was 39 years (range 27–59) and cumulative dose of doxorubicin was 360 mg/m2 (range 225–550). Cardiac function was assessed by echocardiography and (24-h) ECG. The results were compared with those of earlier assessments at 9 years (1992) and 14 years (1997) post-treatment. Results: Systolic dysfunction was found in 27% (9% in 1997; P = 0.02) and diastolic dysfunction in 45% (18% in 1997; P = 0.02). Heart rate variability showed further deterioration compared with earlier results. Conclusions: Twenty-two years after doxorubicin-treatment, bone tumour survivors showed progressive cardiac dysfunction.</description><subject>Adolescent</subject><subject>Adult</subject><subject>anthracyclines</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Blood Pressure - physiology</subject><subject>Bone Neoplasms - complications</subject><subject>Bone Neoplasms - drug therapy</subject><subject>Bone Neoplasms - physiopathology</subject><subject>bone tumour</subject><subject>cardiac toxicity</subject><subject>Child</subject><subject>Doxorubicin - adverse effects</subject><subject>Doxorubicin - therapeutic use</subject><subject>Echocardiography</subject><subject>Electrocardiography</subject><subject>Female</subject><subject>Heart Diseases - chemically induced</subject><subject>Heart Diseases - etiology</subject><subject>Humans</subject><subject>late effects</subject><subject>longitudinal</subject><subject>Longitudinal Studies</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Osteosarcoma - complications</subject><subject>Osteosarcoma - drug therapy</subject><subject>Osteosarcoma - physiopathology</subject><subject>Pharmacology. Drug treatments</subject><subject>Survivors</subject><subject>Time</subject><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkF1LwzAUhoMobk4vvZUgeFmX7zaXMtQJG4IoyG5Cmjajs01m0k7991Y63M05cM7D-8IDwCVGtxhJOtXOeWemTVFjLo7AuJ8yyRDDx2CMJKFJyikbgbMYNwghIYk8BSMsMp6mhI7BbOHdOmnL0ECjQ1FpA62va_-VdFtYORi7sKt2PkToLdSw0XW1dtq1MPeuhG3X-C6cgxOr61he7PcEvD3cv87myeL58Wl2t0gMI7xNiCU2z7SRWBSsKCRniAkuiMxIwS3CgvdnKQhGKUUmtylKM4uZNiW3FBecTsD1kLsN_rMrY6s2fbvrKxWWQhCKJOuhZIBM8DGG0qptqBodfhRG6s-YGoypwVjPX-1Du7wpiwO9V9QDN3tAR6NrG7QzVTxwGWGcE3EormJbfv__dfhQIqUpV_P3laIcLfnqZanm9Bc1CoPP</recordid><startdate>20061001</startdate><enddate>20061001</enddate><creator>Brouwer, CAJ</creator><creator>Gietema, JA</creator><creator>van den Berg, MP</creator><creator>Bink-Boelkens, MTE</creator><creator>Elzenga, NJ</creator><creator>Haaksma, J</creator><creator>Kamps, WA</creator><creator>Vonk, JM</creator><creator>de Vries, EGE</creator><creator>Postma, A</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope></search><sort><creationdate>20061001</creationdate><title>Long-term cardiac follow-up in survivors of a malignant bone tumour</title><author>Brouwer, CAJ ; Gietema, JA ; van den Berg, MP ; Bink-Boelkens, MTE ; Elzenga, NJ ; Haaksma, J ; Kamps, WA ; Vonk, JM ; de Vries, EGE ; Postma, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c425t-2f2fb8ac916d4dd954046562982d5f0165d4d96210730cbf7078f14ace5f31d53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>anthracyclines</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Blood Pressure - physiology</topic><topic>Bone Neoplasms - complications</topic><topic>Bone Neoplasms - drug therapy</topic><topic>Bone Neoplasms - physiopathology</topic><topic>bone tumour</topic><topic>cardiac toxicity</topic><topic>Child</topic><topic>Doxorubicin - adverse effects</topic><topic>Doxorubicin - therapeutic use</topic><topic>Echocardiography</topic><topic>Electrocardiography</topic><topic>Female</topic><topic>Heart Diseases - chemically induced</topic><topic>Heart Diseases - etiology</topic><topic>Humans</topic><topic>late effects</topic><topic>longitudinal</topic><topic>Longitudinal Studies</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Osteosarcoma - complications</topic><topic>Osteosarcoma - drug therapy</topic><topic>Osteosarcoma - physiopathology</topic><topic>Pharmacology. Drug treatments</topic><topic>Survivors</topic><topic>Time</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brouwer, CAJ</creatorcontrib><creatorcontrib>Gietema, JA</creatorcontrib><creatorcontrib>van den Berg, MP</creatorcontrib><creatorcontrib>Bink-Boelkens, MTE</creatorcontrib><creatorcontrib>Elzenga, NJ</creatorcontrib><creatorcontrib>Haaksma, J</creatorcontrib><creatorcontrib>Kamps, WA</creatorcontrib><creatorcontrib>Vonk, JM</creatorcontrib><creatorcontrib>de Vries, EGE</creatorcontrib><creatorcontrib>Postma, A</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brouwer, CAJ</au><au>Gietema, JA</au><au>van den Berg, MP</au><au>Bink-Boelkens, MTE</au><au>Elzenga, NJ</au><au>Haaksma, J</au><au>Kamps, WA</au><au>Vonk, JM</au><au>de Vries, EGE</au><au>Postma, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-term cardiac follow-up in survivors of a malignant bone tumour</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2006-10-01</date><risdate>2006</risdate><volume>17</volume><issue>10</issue><spage>1586</spage><epage>1591</epage><pages>1586-1591</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><abstract>Background: Longitudinal studies of cardiac function in long-term childhood cancer survivors are scarce and frequently concern a median follow-up shorter than 13 years. Patients and methods: Cardiac assessment was performed in 22 doxorubicin-treated long-term survivors of a malignant bone tumour at median 22 years (range 15–27.5) post-treatment. Age at follow-up was 39 years (range 27–59) and cumulative dose of doxorubicin was 360 mg/m2 (range 225–550). Cardiac function was assessed by echocardiography and (24-h) ECG. The results were compared with those of earlier assessments at 9 years (1992) and 14 years (1997) post-treatment. Results: Systolic dysfunction was found in 27% (9% in 1997; P = 0.02) and diastolic dysfunction in 45% (18% in 1997; P = 0.02). Heart rate variability showed further deterioration compared with earlier results. Conclusions: Twenty-two years after doxorubicin-treatment, bone tumour survivors showed progressive cardiac dysfunction.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>16857723</pmid><doi>10.1093/annonc/mdl156</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2006-10, Vol.17 (10), p.1586-1591 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_proquest_journals_196623094 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adolescent Adult anthracyclines Antineoplastic agents Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Biological and medical sciences Blood Pressure - physiology Bone Neoplasms - complications Bone Neoplasms - drug therapy Bone Neoplasms - physiopathology bone tumour cardiac toxicity Child Doxorubicin - adverse effects Doxorubicin - therapeutic use Echocardiography Electrocardiography Female Heart Diseases - chemically induced Heart Diseases - etiology Humans late effects longitudinal Longitudinal Studies Male Medical sciences Middle Aged Osteosarcoma - complications Osteosarcoma - drug therapy Osteosarcoma - physiopathology Pharmacology. Drug treatments Survivors Time |
| title | Long-term cardiac follow-up in survivors of a malignant bone tumour |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T22%3A07%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-term%20cardiac%20follow-up%20in%20survivors%20of%20a%20malignant%20bone%20tumour&rft.jtitle=Annals%20of%20oncology&rft.au=Brouwer,%20CAJ&rft.date=2006-10-01&rft.volume=17&rft.issue=10&rft.spage=1586&rft.epage=1591&rft.pages=1586-1591&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdl156&rft_dat=%3Cproquest_cross%3E1141009781%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=196623094&rft_id=info:pmid/16857723&rfr_iscdi=true |